Discover Our Hematological Malignancies Trial Portfolio With Cutting-Edge Laboratory Solutions

With a track record of conducting 80 hematological malignancy trials since 2018, Cerba Research provides comprehensive laboratory solutions for clinical trials focused on various cancers, including multiple myeloma, acute myeloid leukemia, and lymphomas.

Our expertise lies in advanced assays like flow cytometry, next-generation sequencing (NGS), and immunohistochemistry (IHC), supporting the development of innovative cell and gene therapies. Notably, we partnered in the market authorization of three CAR T-cell therapies. Our global network of laboratories, standardized protocols, and advanced equipment ensure high-quality data and efficient processing for hematological malignancy trials across all phases.

Download the brochure below to explore our full capabilities and learn more about how Cerba Research can support your hematological malignancy trials.